Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BioAlliance Pharma, a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV, has appointed Pierre Morgon as its new COO.
Subscribe to our email newsletter
Mr Morgon joins from Schering-Plough France, where he managed the primary care operations in France for two years and the partnership with MSD.
From 2004 to 2006, he was vice president of hospital operations at Bristol Myers Squibb. From 2003 to 2004, he served as general manager of Yamanouchi Pharma France and prepared the merger with Fujisawa.
Dominique Costantini, co-founder, president and CEO of BioAlliance Pharma and Gilles Avenard, co-founder and COO, said: “As COO, Pierre Morgon will focus on the commercial operations across all territories and oversee the execution of the pricing and product launch strategy by the partners. We are delighted to add Pierre to the management board and we are looking forward to this next phase of the development of BioAlliance.”